|
2023
|
Invention
|
Therapeutic methods for treating als. Disclosed are therapeutic methods for reducing the rate of ... |
|
|
Invention
|
Prophylactic methods for treating als. Amyotrophic lateral sclerosis (ALS) is a debilitating and ... |
|
|
Invention
|
Prophylactic methods for treating als. Disclosed are prophylactic methods for delaying the onset ... |
|
|
Invention
|
Synergistic combination therapy for treating als. Disclosed are methods for inhibiting the progre... |
|
|
Invention
|
Methods for monitoring patient response to treatment of retinal oxidative diseases. Disclosed are... |
|
2022
|
Invention
|
Methods for inhibiting the progression of neurodegenerative diseases. Disclosed are methods for i... |
|
|
Invention
|
Methods for inhibiting the progression of neurodegenerative diseases.
Disclosed are methods for ... |
|
|
Invention
|
Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof.
Disclosed a... |
|
|
Invention
|
Methods for assessing a patient's response to treatment of a neurodegenerative disease with deute... |
|
|
Invention
|
Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof. Disclosed ar... |
|
2021
|
Invention
|
Site-specific isotopic labeling of 1,4-diene systems. Methods for preparing isotopically modified... |
|
|
Invention
|
Site-specific isotopic labeling of 1,4-diene systems.
Methods for preparing isotopically modifie... |
|
|
Invention
|
Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof. Discl... |
|
|
Invention
|
Methods for treating tauopathy. Disclosed are uses of isotopically modified polyunsaturated compo... |
|
|
Invention
|
Deuterated polyunsaturated fatty acids or esters thereof for cosmetic applications. Disclosed are... |
|
2019
|
Invention
|
Deuterated compounds, compositions, and uses. Deuterated polyunsaturated fatty acid ("PUFA") comp... |
|
|
Invention
|
Stabilized polyunsaturated compounds and uses thereof. Methods are provided for treating a subjec... |
|
|
Invention
|
Isotopically modified composition and therapeutic uses thereof. Isotopically modified polyunsatur... |
|
2018
|
Invention
|
Alleviating oxidative stress disorders with pufa derivatives.
Some aspects of the invention prov... |
|
2017
|
Invention
|
Isotopically modified components and therapeutic uses thereof. Methods are provided of identifyin... |
|
|
Invention
|
Isotopically modified composition and therapeutic uses thereof.
This disclosure relates to isoto... |
|
|
Invention
|
Isotopically modified composition and therapeutic uses thereof. This disclosure relates to isotop... |
|
2016
|
Invention
|
Improving quality of mitochondrial dna measurements for use in assessing mitochondrial dysfunctio... |
|
|
Invention
|
Site-specific isotopic labeling of 1, 4-diene systems. Methods for preparing isotopically modifie... |
|
2015
|
Invention
|
Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized poly... |
|
2012
|
Invention
|
Oxidative retinal diseases. Some aspects of the invention provide for a method of treating Wet an... |
|
|
Invention
|
Impaired energy processing disorders and mitochondrial deficiency. Some aspects of the invention ... |
|
|
Invention
|
Neurodegenerative disorders and muscle diseases implicating pufas. Some aspects of the invention ... |
|
|
Invention
|
Disorders implicating pufa oxidation. Some aspects of the invention provide for a method of treat... |
|
2010
|
Invention
|
Alleviating oxidative stress disorders with pufa derivatives. Some aspects of the invention... |
|
|
Invention
|
Alleviating oxidative stress disorders with pufa derivatives. Some aspects of the invention provi... |
|
2009
|
Invention
|
Therapies for cancer using isotopically substituted lysine. Methods of treatment and substa... |
|
|
Invention
|
Therapeutic substances that modulate genome methylation. Compounds containing nucleic acid bases ... |
